viewAllocate Software

Allocate Software sales rally in second quarter


Allocate Software's (LON:ALL) sales have picked up strongly in the latest three months reversing what had been a weak start to the current year.

The hospital software group said total sales for the six months to November are now expected to be slightly ahead of the £16 mln in first half of last year, driven by strong performances from HealthRoster, Allocate’s core hospital rota software, and its new cloud computing service.

HealthRoster enjoyed its second highest billing quarter with seven renewals closed in the half year with the level of renewals overall remaining at 100%.

Cloud computing contracts, meanwhile, now total 13, which includes two multi-year contracts with major teaching hospitals.

Other areas of the business also continue to perform satisfactorily, Allocate said.

Ian Bowles, chief executive, added the growth in cloud services and subscription revenues should continue, with Allocate now offering customers the option of either their own on-premise service or a fully managed one.

“After a very slow first quarter, our performance in the second quarter met management expectations, with every contract forecast for the quarter being closed. In addition our policy of driving more business on to a recurring basis will benefit future reporting periods.”

“"Pipeline levels in our healthcare businesses in Sweden and Australia remain high and I am delighted to see that so many NHS Trusts are still seeking to engage with us about our products and solutions.

"I am confident that we will carry the strong momentum of the second quarter into the rest of the financial year, building the quality and predictability of our revenue streams as we do so."


Quick facts: Allocate Software

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Orthocell's Paul Anderson hails FDA approval for dental bone and tissue...

Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US....

3 days ago

2 min read